Furthermore, there are reported (in vitro and in vivo) results in [36] which demonstrate that the suppression of HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1) by siRNA and dipyridamole enhances the antitumor properties of trametinib in colon cancer cells. The gene discussed is HMGCS1; the disease is malignant colon neoplasm.